<?xml version="1.0" encoding="UTF-8"?>
<p id="P11">Acyclovir is also approved by the US Food and Drug Administration (FDA) for the treatment of VZV
 <sup>
  <xref ref-type="bibr" rid="R11">11</xref>,
  <xref ref-type="bibr" rid="R12">12</xref>
 </sup>; however, young immunocompetent patients with zoster may not require treatment if the lesions are localized and have been present for more than 72 hours. Intravenous acyclovir is recommended for patients with disseminated zoster disease or visceral involvement. Acyclovir treatment of zoster reduces duration of viral shedding, formation of new lesions, and short- and long-term neuralgia.
 <sup>
  <xref ref-type="bibr" rid="R13">13</xref>
 </sup> Therapy should be started early, but even delayed initiation of acyclovir may still be beneficial in immunocompromised patients. Short-course prednisone may be added as an adjunct to acyclovir treatment of zoster to improve quality of life, especially in elderly patients.
</p>
